Fitxers

878443.pdf (3.53 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-02-01

Llicència de publicació

cc-by (c) Bonilla-Vidal, L. et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227407

Nanostructured lipid carriers co-encapsulating Apigenin and Melatonin: An innovative strategy against cancer

Títol de la revista

Autors

Director/Tutor

Contribució addicional

ISSN de la revista

Títol del volum

Resum

Cancer remains a global health concern, being one of the leading causes of premature death worldwide. In 2020, around 19 million people were diagnosed with cancer, leading to approximately 10 million deaths [1], [2]. Conventional cancer therapies, including chemotherapy and radiotherapy, often exhibit adverse effects and suboptimal treatment outcomes. Specifically, chemotherapy is frequently administered to over 50 % of cancer patients, but it can simultaneously impact both healthy and cancerous cells, causing significant side effects. Moreover, these therapies can induce chemoresistance, compromising their effectiveness over time [3], [4]. As a result, there is an urgent need for the development of innovative therapeutic strategies to address these limitations.

Recurs relacionat

https://doi.org/10.1016/j.matdes.2024.113573

Matèries

Càncer, Melatonina, Nanotecnologia, Epigenètica

Matèries (anglès)

Cancer, Melatonin, Nanotechnology, Epigenetics

Citació

Col·leccions

Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Citació

BONILLA VIDAL, Lorena, et al. Nanostructured lipid carriers co-encapsulating Apigenin and Melatonin: An innovative strategy against cancer. Materials & Design. 2025. Vol. 250. ISSN 0264-1275. [consulted: 30 of September of 2026]. Available at: https://hdl.handle.net/2445/227407

Exportar metadades

JSON - METS

Compartir registre